Travis Whitfill
@twhitfill
Followers
4K
Following
13K
Media
2K
Statuses
8K
Biotech/healthcare. Assistant Professor Adjunct @Yale. Cofounder & COO @azitrainc. Former partner Bios Partners. PhD @IIPP_UCL. MPH @YaleSPH ‘14. Opinions mine
New York
Joined January 2009
Just to reiterate Fauci’s track record: - 41st most cited researcher of all time - 8th most cited immunologist (of 2.2M) - Presidential Medal of Freedom - Huge contributions to AIDS epidemic - 45 honorary doctorates - H-index above 200
COVID Update May 14: The attacks on Anthony Fauci is a mis-placed hit job. And it’s actually dangerous. 1/
76
1K
4K
Azitra addresses false report circulating that it had priced a $44mm offering. $AZTR asserts that this is untrue. The latest capital raise we see was in January. An April announcement was made for a share purchase agreement with Alumni. https://t.co/chVYhdz8y4
ir.azitrainc.com
BRANFORD, Conn. , Nov. 7, 2025 /PRNewswire/ -- Azitra , Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
1
2
6
There are reports circulating around Azitra with respect to issuance of stock by the company. These reports are false. Please refer to our IR page for official press releases and more information: https://t.co/ql6fjBhXZx $AZTR
ir.azitrainc.com
The Investor Relations website contains information about Azitra, Inc.'s business for stockholders, potential investors, and financial analysts.
4
4
7
Thrilled to announce initial safety data from our ongoing Phase 1B clinical trial in Netherton syndrome. I’ll be presenting at BIO today at 12pm to discuss our latest updates. $AZTR https://t.co/646DkLc5Xu
prnewswire.com
/PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision...
0
0
0
Check out @azitrainc's @twhitfill on the #RARECast #podcast - Engineering Skin Bacteria to Be Live Biotherapeutics - digging in on #NethertonSyndrome @lmgbio #precisionderm #dermatology
podcasts.apple.com
Podcast Episode · RARECast · 03/27/2025 · 28m
0
1
3
.@twhitfill @azitrainc , discusses Netherton syndrome, the company’s platform technology for engineering live biotherapeutic products, and why it takes more than simply inserting a gene into a desired bacteria to produce these treatments. https://t.co/lLIrQGQ4Jf
0
1
1
It was an honor being on RARECast this week. Thanks Daniel Levine for having me! https://t.co/GTmnGBMG17
0
0
0
Looking forward to presenting next week at the Microbiome Times Forum in Brussels! @azitrainc $AZTR https://t.co/zSBamP6gSg
1
2
2
Looking forward to presenting next week at the Microbiome Times Forum in Brussels! @azitrainc $AZTR https://t.co/zSBamP6gSg
1
2
2
@KiraDineen @DNATodayPodcast @twhitfill More from @azitrainc's @twhitfill on the @DNATodayPodcast - What led you to Co-Found Azitra? What need did you see? The potential of targeting the skin w/ synthetic biology methods & huge unmet need in a variety of severe, under addressed derm indications https://t.co/i9cAKrCM1r
0
1
2
After years of working full time and getting a PhD part time at @IIPP_UCL, I passed my PhD defense today! Huge thank you @MazzucatoM for all the guidance over the years and my wonderful examiners @CeciliaRikap @SuerieMoon!!
0
0
2
It's rare disease month, and I thoroughly enjoyed joining @KiraDineen at BIO CEO this week on her podcast @DNATodayPodcast to talk about our engineered skin commensal platform at Azitra to treat rare skin diseases. 🧬
dnapodcast.com
Interviews recorded at BIO’s CEO and Investor Conference with two biotech executives: Cellinfinty Bio’s Dr. Premal Patel and Azitra’s Dr. Travis Whitfill.
0
1
2
I’ll be giving at talk at 3:45p ET today at the BIO CEO & Investor conference $AZTR https://t.co/kvkk4sfniI
ir.azitrainc.com
BRANFORD, Conn. , Feb. 3, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology,...
2
1
3
I've admittedly often complained about high indirect costs on my grants (my worst offender was Jackson Labs at 90%), but indirect costs are critical in supporting fundamental academic research. Here's a great infographic showing where these funds go:
Last year, $9B of the $35B that the National Institutes of Health (NIH) granted for research was used for administrative overhead, what is known as “indirect costs.” Today, NIH lowered the maximum indirect cost rate research institutions can charge the government to 15%, above
0
0
1
This is a great graphic! I’ve been looking for something like this. I can never seem to keep track of who sold which consumer division to whom.
Here is an excellent graph which demonstrates how each one of the big Pharma companies - that were once diversified conglomerates, has unloaded its side businesses in order to focus on developing Biotech-style medicines & treatments. $NVO $BMY $AZN $PFE $ABBV $LLY $JNJ $MRK $XBI
1
0
0
I submitted an AHRQ grant last month with a review scheduled next week Reached out to PO to see if it’s still meeting. Email returned; no longer works there Reached out to other contact; study section cancelled Scientific progress across the board is being unilaterally halted.
0
1
2
The entire public health/biopharma sector has been disrupted. Some personal anecdotes/impacts - Previous job offers rescinded - Travel plans for the year cancelled - Grants essentially frozen - No disease surveillance comms - No more diversity for agencies OR clinical trials (??)
1
1
5
The US decision to withdraw from the WHO undermines global health cooperation. The @WHO Council on the Economics of #HealthForAll (@Economy4Health), which I co-chaired, underlined why collective investment in #HealthForAll is critical for people and economies. The evidence is
5
57
133
Remember the headlines last fall saying to throw out black spatulas? Turns out the authors of the study miscaulated the EPA's exposure guidelines by an order of magntitude (42k ng/day vs. 420k ng/day). Soo it's probably fine :) https://t.co/KrK8govxQd
0
0
0